Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FOLR1

FOLR1

Brief Information

Name:Folate receptor alpha
Target Synonym:FRalpha,KB cells FBP,Adult folate-binding protein,Folate receptor 1,Folate receptor alpha,FR-alpha,FOLR1,Ovarian Tumor-Associated Antigen MOv18,Folate Receptor 1 (Adult),Folate Receptor, Adult,FOLR,FBP,Folate Binding Protein,FRα
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:11
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

FO1-HP2H9-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-FOLR1 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human FOLR1, His Tag (Cat. No. FO1-HP2H9) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

FO1-HF2H8-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of Anti-FOLR1 CAR-293 cells were stained with 100 μL of 3 μg/mL of FITC-Labeled Human FOLR1, His Tag (Cat. No. FO1-HF2H8) and negative control protein respectively, FITC signals was used to evaluate the binding activity (QC tested).

FO1-H52H1-ELISA
Human FOLR1, His TagHuman FOLR1, His Tag (Cat. No. FO1-H52H1) ELISA bioactivity

Immobilized Folic Acid-BSA Conjugate at 5 μg/mL (100 μL/well) can bind Human FOLR1, His Tag (Cat. No. FO1-H52H1) with a linear range of 5-78 ng/mL (QC tested).

FO1-HF2H8-MALS-HPLC
FITC-Labeled Human FOLR1, His Tag (Cat. No. ) MALS images

The purity of FITC-Labeled Human FOLR1, His Tag (Cat. No. FO1-HF2H8) is more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.

Bioactivity-ELISA
FITC-Labeled Human FOLR1, His TagFITC-Labeled Human FOLR1, His Tag (Cat. No. FO1-HF2H8) ELISA bioactivity

Immobilized Folic acid-BSA conjugate at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human FOLR1, His Tag (Cat. No. FO1-HF2H8) with a linear range of 0.078-1.25 μg/mL (QC tested).

Synonym Name

FOLR-1,FBP,FOLR

Background

Folate Receptor 1 (FOLR1) is also known as Folate receptor alpha, Folate Binding Protein (FBP), FOLR, and is a member of the folate receptor (FOLR) family. Members of this gene family have a high affinity for folic acid and for several reduced folic acid derivatives, and mediate delivery of 5-methyltetrahydrofolate to the interior of cells. Mature FOLR1 is an N-glycosylated protein that is anchored to the cell surface by a GPI linkage. FOLR1 is predominantly expressed on epithelial cells and is dramatically upregulated on many carcinomas. FOLR1 is internalized to the endosomal system where it dissociates from its ligand before recycling to the cell surface. A soluble form of FOLR1 can be proteolytically shed from the cell surface into the serum and breast milk. Defects in FOLR1 are the cause of neurodegeneration due to cerebral folate transport deficiency (NCFTD). NCFTD is an autosomal recessive disorder resulting from brain-specific folate deficiency early in life.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Pafolacianine Sodium Pteroyl-L-Tyr-S0456; OTL-38; EC-17; OTL-0038 Approved On Target Laboratories Inc Cytalux United States Ovarian Neoplasms On Target Laboratories Inc 2021-11-29 Ovarian Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms Details
Folinic Acid FTHF Approved Colorectal Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CBP-1008 CBP-1008 Phase 1 Clinical Coherent Biopharma Suzhou Co Ltd Ovarian Neoplasms; Solid tumours; Breast Neoplasms; Carcinoma, Squamous Cell Details
Vintafolide EC-145; MK-8109 Phase 2 Clinical Novartis Pharma Ag Ovarian Neoplasms; Solid tumours; Adenocarcinoma of Lung; Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Noscapine-folate conjugate Phase 1 Clinical Emory University Hematologic Neoplasms; Inflammation Details
4S-CAR-FRa 4S-CAR-FRa Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Carcinoma, Transitional Cell; Urinary Bladder Neoplasms Details
MOv19-BBz CAR-T cells Therapy Phase 1 Clinical University Of Pennsylvania Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
MOv-18 IgE MOv-18 IgE Phase 1 Clinical King'S College London, Cancer Research Uk Ovarian Neoplasms Details
Farletuzumab MORAb-003 Phase 3 Clinical Morphotek Ovarian Neoplasms; Solid tumours; Adenocarcinoma of Lung; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
MORAb-202 MORAb-202 Phase 2 Clinical Eisai Co Ltd, Morphotek, Bristol-Myers Squibb Company Solid tumours Details
STRO-002 SP-7219; SP-7675; SP-7676; STRO-002; DBCO-Alexa647-conjugated SP7219 Phase 1 Clinical Sutro Biopharma Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Endometrioid Details
Arfolitixorin ISO-901; 6R-MTHF Phase 3 Clinical Isofol Medical Ab Rectal Neoplasms; Colonic Neoplasms; Osteosarcoma; Colorectal Neoplasms Details
Mirvetuximab soravtansine IMGN-853; M9346-Asulfo-SPDB-DM4 Phase 3 Clinical Immunogen Inc Ovarian Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message